Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 42, 2008, Pages 16302-16307

  Cohen, Ted ^a,b   Colijn, Caroline ^b,c   Murray, Megan ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bacillus Calmette Gu rin; Mathematical model; Strain replacement

Indexed keywords

BCG VACCINE;

ARTICLE; DISEASE ACTIVITY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; INFECTION CONTROL; INFECTION PREVENTION; MASS IMMUNIZATION; MATHEMATICAL MODEL; MICROBIAL DIVERSITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS;

MODELS, BIOLOGICAL; TUBERCULOSIS; TUBERCULOSIS VACCINES;

MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 55849118488     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0808746105     Document Type: Article

References (49)

1. Gupta UD, Katoch VM, McMurray DN (2007) Current status of TB vaccines. Vaccine 25:3742-3751.
2. Kaufmann SH (2006) Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6:699-704.
3. Musser JM, Amin A, Ramaswamy S (2000) Negligible genetic diversity of mycobacterium tuberculosis host immune system protein targets: Evidence of limited selective pressure. Genetics 155:7-16.
4. Sreevatsan S, et al. (1997) Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 94:9869-9874.
5. Fleischmann RD, et al. (2002) Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 19:5479-5490.
6. Gutacker MM, et al. (2006) Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis 193:121-128.
7. Filliol I, et al. (2006) Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: Insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 188:759-772.
8. Thwaites G, et al. (2008) Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 46:1363-1368.
9. López B, et al. (2003) A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 133:30-37.
10. Valway SE, et al. (1998) An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 338:633-639.
11. Hanekom M, et al. (2007) Evidence that the spread of Mycobacterium tuberculosis strains with the Beijing genotype is human population dependent. J Clin Microbiol 45:2263-2266.
12. Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7:328-337.
13. van Crevel R, et al. (2001) Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment. Emerg Infect Dis 7:880-883.
14. Mendelson M, Walters S, Smith I, Kaplan G (2005) Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis. Tuberculosis 85:407-413.
15. Reed MB, et al. (2004) A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87.
16. Pheiffer C, Betts JC, Flynn HR, Lukey PT, van Helden P (2005) Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology 151:1139-1150.
17. Dormans J, et al. (2004) Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin Exp Immunol 137:460-468.
18. Rindi L, et al. (2007) Variation of the expression of Mycobacterium tuberculosis ppe44 gene among clinical isolates. FEMS Immunol Med Microbiol 51:381-387.
19. van Soolingen D, et al. (1995) Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 33:3234-3238.
20. Anh DD, et al. (2000) Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 6:302-305.
21. Kremer K (2005) PhD thesis. (Univer of Amsterdam), pp 234-247.
22. Abebe F, Bjune G (2006) The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: Is there a link? Clin Exp Immunol 145:389-397.
23. Tsenova L, et al. (2007) BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine 25:5126-5132.
24. Grode L, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115:2472-2479.
25. Hebert AM, et al. (2007) DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: Implications for vaccine efficacy. Infect Immun 75:5798-5805.
26. Martcheva M, Bolker BM, Holt RD (2008) Vaccine-induced pathogen strain replacement: What are the mechanisms? J R Soc Interface 5:3-13.
27. Iannelli M, Martcheva M, Li X-Z (2005) Strain replacement in an epidemic model with super-infection and perfect vaccination. Math Biosci 195:23-46.
28. Warren RM, et al. (2004) Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 169:610-614.
29. Chiang C-Y Riley LW (2005) Exogenous reinfection in tuberculosis. Lancet Infect Dis 5:629-636.
30. Manca C, et al. (1999) Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 162:6740-6746.
31. Manca C, et al. (2001) Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA 98:5752-5757.
32. Manca C, et al. (2004) Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun 72:5511-5514.
33. de Jong BC, et al. (2006) Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J Infect Dis 193:1279-1286.
34. World Health Organization (2008) Global Tuberculosis Control:Surveillance, Planning, Financing. (World Health Organization, Geneva), WHO/HTM/TB/2008.393.
35. Lietman T, Blower SM (2000) Potential impact of tuberculosis vaccines as epidemic control agents. Clin Infect Dis 30(Suppl 3):S316-S322.
36. Ziv E, Daley CL, Blower S (2004) Potential public health impact of new tuberculosis vaccines. Emerg Infect Dis 10:1529-1535.
37. Young D, Dye C (2006) The development and impact of tuberculosis vaccines. Cell 124:683-687.
38. Bhunu CP, Garira W, Mukandavire Z, Magombedzea G (2008) Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control. J Theor Biol 254:633-649.
39. McLean AR (1995) Vaccination, evolution and changes in the efficacy of vaccines: A theoretical framework. Proc Biol Sci 261:389-393.
40. Lipsitch M (1997) Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 94:6571-6576.
41. Drobniewski F, et al. (2002) Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: Dominance of the Beijing strain family. Emerg Infect Dis 8:1320-1326.
42. Cox HS, et al. (2005) The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 6:134.
43. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis (2006) Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 12:736-743.
44. Sanchez MA, Blower SM (1997) Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example. Am J Epidemiol 145:1127-1137.
45. Dye C, Espinal MA (2001) Will tuberculosis become resistant to all antibiotics? Proc Biol Sci 268:45-52.
46. Gandon S, Mackinnon MJ, Nee S, Read AF (2001) Imperfect vaccination: Some epidemiological and evolutionary consequences. Nature 414:751-756.
47. Ganusov VV, Antia R (2006) Imperfect vaccines and the evolution of pathogens causing acute infections in vertebrates. Evolution Int J Org Evolution 60:957-969.
48. Dye C, Williams BG (2007) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 23:653-662.
49. Nowak MA, May RM (1994) Superinfection and the evolution of parasite virulence. Proc Roy Soc B 255:81-89.